 Subcutaneous sumatriptan acute treatment migraine Sumatriptan International Study Group double-blind placebo-controlled multicentre studies efficacy tolerability subcutaneous injections mg mg sumatriptan acute treatment migraine Data total patients studies primary endpoint efficacy reduction headache severity severe moderate headache doses sumatriptan effective placebo symptoms response dose-related effective response treatment min patients mg sumatriptan patients mg sumatriptan placebo Sumatriptan majority adverse events mild transient frequent complaint irritation pain site injection changes laboratory values ECG readings unaltered treatment basis results mg subcutaneous dose evaluation large-scale studies